Sprouty proteins are potent receptor tyrosine kinase inhibitors that antagonize growth factor signaling and are involved in lung development. However, little is known about the regulation or targets of Sprouty-4 (Spry4) in lung cancer. Our study aimed to determine the role of Spry4 in non-small cell lung cancer (NSCLC). We found that Spry4 mRNA expression was decreased in NSCLC cell lines and in dysplastic lung cell lines compared with a nontransformed cell line, suggesting that Spry4 has tumor-suppressing activity. When Spry4 was stably transfected into H157 and H2122 NSCLC cell lines, decreased migration and invasion were observed. Matrix metalloproteinase-9 activity was decreased, and the expression of matrix metalloproteinase inhibitors TIMP1 and CD82 were increased. Stable expression of Spry4 led to reduced cell growth and reduced anchorageindependent growth in NSCLC cell lines, along with upregulation of tumor suppressors p53 and p21. Changes in epithelial and mesenchymal markers indicated that Spry4 expression induces a reversal of the epithelial to mesenchymal transition characteristic of tumor cells. Treatment of a nontransformed lung epithelial cell line with short hairpin RNA to Spry4 led to the decreased expression of epithelial markers and increased cell growth, supporting the concept of Spry4 acting as a tumor suppressor. We showed that the activity of the Spry4 promoter is increased by Wnt7A/Fzd9 signaling through peroxisome proliferator-activated receptor γ. These data present previously undescribed targets of Spry4 and suggest that Spry4 is a downstream target of Wnt7A/Fzd 9 signaling. Spry4 may have efficacy in the treatment of NSCLC. Mol Cancer Res; 8(6); 833-43. ©2010 AACR.
Introduction
Sprouty (Spry) proteins were first identified as potent receptor tyrosine kinase (RTK) inhibitors that modulate tracheal branching in Drosophila (1, 2) . Subsequent studies identified four vertebrate Spry proteins with highly conserved COOH-terminal and Spry domains, and variable NH 2 -terminal domains (3) . The interaction of Spry proteins with RTK pathways depends on the specific Spry and cellular context. Sprys have been shown to inhibit epidermal growth factor (EGF) receptor, fibroblast growth factor (FGF) receptor, vascular endothelial growth factor receptor, and platelet-derived growth factor receptor (4) (5) (6) . Sprys can bind to growth factor receptor binding protein 2 or son of sevenless homolog 1 (SOS) to disrupt the receptor complex and interfere with extracellular signalregulated kinase (ERK)/mitogen-activated protein kinase (MAPK) activation. Spry2 has been shown to interact with c-CBL to inhibit EGF-mediated ERK/MAPK signaling (3) . Downregulation of Spry1 has been observed in breast and prostate cancer; of Spry2 in breast, prostate, and liver cancer; and of Spry4 in prostate cancer (7, 8) . Spry4 seems to act as a marker of treatment response in gastrointestinal tumors, and Spry1 presence is associated with a good prognosis in renal cell carcinoma patients (8) . A protective role for Spry2 in the lung has been described in vitro, as well as in vivo in a urethane model of non-small cell lung cancer (NSCLC) and in a germline KRAS mutation model of lung cancer (9) (10) (11) .
The Wnt family of proteins control diverse developmental pathways and act in cooperation with the Frizzled (Fzd) family of seven-membrane spanning G-coupled protein receptors. Increased activity of the canonical Wnt/β-catenin signaling pathway has been associated with oncogenic stimulation in several types of cancer (12) (13) (14) (15) (16) . In contrast, our previous work has shown Wnt7A is lost in NSCLC and activation of Wnt7A signaling leads to the reversal of the transformed phenotype in NSCLC (17) . Wnt7A binds to the Fzd9 receptor and signals through to activate the tumor suppressor peroxisome proliferatoractivated receptor γ (PPARγ), but the downstream targets of PPARγ are largely unknown (18, 19) . PAPRγ and its synthetic agonists, such as ciglitazone and rosiglitazone, inhibit transformed growth and metastasis, promote epithelial differentiation, and have shown tumor prevention efficacy (20) (21) (22) (23) (24) (25) .
We previously observed that Spry4 expression is upregulated with the activation of Wnt7A and Fzd9 by quantitative PCR (QPCR) and immunoblot in NSCLC, suggesting a role for Spry4 in a pathway outside of RTK signaling (17) . However, the specific involvement of Spry4 in this noncanonical Wnt signaling pathway is unknown. Spry4 has been shown to inhibit FGF pathways in cell lines and mice, but unlike other members of the Spry family, Spry4 has not been shown to inhibit EGF signaling (5, 26, 27) . Evaluation of mouse organogenesis has identified Spry4 expression in the lung epithelium of the developing embryo, but characterization of Spry4 expression in adult lung tissue still needs to be completed (28) . There is clearly a need for further studies exploring the role of Spry4 in the context of the lung epithelium. In the study presented here, we examined Spry4 activity in NSCLC and found that it is lost in cancer cell lines and dysplastic cell lines. We identified Wnt7A/Fzd9 and PPARγ as regulators of Spry4 and described new targets of Spry4 known to be involved in suppressing tumor growth and metastasis. We showed that the reexpression of Spry4 results in decreased transformed cell growth, decreased migration and invasion, and increased differentiation of NSCLC cells.
Materials and Methods
Cell culture and retrovirus-mediated gene transfer NSCLC and Beas2B (a human nontransformed lung epithelial cell line) cell lines were cultured in RPMI 1640 supplemented with 10% fetal bovine serum at 37°C in a humidified 5% CO 2 incubator. The human bronchial epithelial cell (HBEC) cell line was cultured in Bronchial Epithelial Basal Media at 37°C in a humidified 5% CO 2 incubator. Cell lines were obtained from the University of Colorado Cancer Center Cell Line Core in 1995, except the HBEC cell line, which was obtained in 2009 from Dr. Robert Doebele at the University of Colorado Denver, Denver, CO. Morphology of all cell lines was monitored twice weekly, and stocks of cell lines were passaged no >10 times for use in experiments. The Spry4/PCDNA3 vector was kindly provided by Diane Harris (University of California at Los Angeles, Los Angeles, CA). Spry4 was ligated into the retroviral vector LPCX (Clontech), and 3 μg of the expression vector with Spry4 was packaged into a replication-defective retrovirus using 293t cells as previously described (17) . H157 and H2122 cell lines were transduced, selected, and maintained in growth medium containing puromycin (1 μg/mL). The H157 Wnt7A/ Fzd9 cell line was previously described (17) . The B2B Spry4 knockdown cell lines were created using Spry4 short hairpin RNA (shRNA) in a lentiviral vector from Open Biosystems. 293t cells were transfected with packaging vectors and 1 μg of the Spry4 lentiviral shRNA or negative lentiviral control plasmid, and then B2B cells were transduced with the resulting viral media. Cell lines were selected and maintained with growth medium containing puromycin (1 μg/mL).
Cell growth, MTS assay, soft agar assay, and caspase assay
For the cell growth assay, 50,000 cells were seeded in triplicate per well of a 24-well culture plate in complete growth medium. Cells were counted for 6 days using a hemocytomoeter. For the soft agar assay, 2,500 cells were seeded in triplicate in a six-well plate and the assay was conducted as previously described (18) . The data are presented as cloning efficiency: the mean number of colonies per well divided by the number of cells plated. Activity of caspase-3/7 was analyzed using a Caspase-Glo 3/7 Assay (Promega). For the MTS assay (Promega), 500 cells per well were seeded in triplicate for each cell line. At 24, 48, and 72 hours, 20 μL of MTS reagent was added to each well, incubated for 1 hour at 37°C, and the results analyzed in a 96-well plate reader at 490 nm. The sample data were normalized to background readings of media only.
Quantitative real-time PCR
RNA was extracted from cells with RNeasy (Qiagen, Inc.), and 5 μg of RNA were converted to cDNA. RNA from primary dysplastic cell cultures was a gift from Dr. Dan Merrick (Veterans Affairs Medical Center, Denver, CO). Dysplastic cell cultures are arbitrarily numbered 1 to 13. Primer sequences for Spry4 were F 5′-CCAG-GATGTCACCCAC CATTG-3′and R 5′-TGTGCTGC-TGCTGCTC-3′, and F 5′-GCCAAATATG ATGACAT-CAAGAAGG-3′ and R-5′GGTGTCGCTGTTGAAGT-CAGAG-3′ for glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Integrated DNA Technologies). Primer sets for p53, p21, CD82, TIMP1, KRT8, KRT18, and Vimentin were obtained from SABiosciences and are available on the manufacturer's Web site (SABioscience). PCR conditions were 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds, and 60°C for 1 minute. Spry4 and GAPDH reactions included 2 μL of cDNA, SYBRGreen Jumpstart Taq Readymix (Sigma Aldrich), 200 nmol/L primers, and 2 mmol/L MgCl 2 in a 25-μL volume. Superarray PCR required the RT 2 Real-time SYBRGreen PCR Master Mix (SABioscience) and 1 μL of Superarray qRT-PCR Primer Assay in a 25-μL volume. GAPDH was used to normalize all samples. The QPCR data are presented as fold changes in normalized mRNA levels in control versus experimental samples and are the average of at least triplicate experiments with SEM presented as error bars.
Transfections and luciferase assays
The reporter plasmids PPAR response element (PPRE; 3 μg) and Spry4 promoter-luciferase (3 μg; kindly provided by Dr. Warburton, University of Southern California, Los Angeles, CA), expression plasmids wild-type PPARγ (3 μg) and Spry4 (3 μg), and β-galactosidase control plasmids (3 μg) were transfected into H157 and H2122 cells using Lipofectamine Reagent (Invitrogen). Truncated Spry4 luciferases were constructed from the fulllength promoter luciferase (−4,446) at −1,182, −418, and −31 bp from the transcription start site. Truncated Spry4 luciferases −4,446, −1,182, and −418 were gifts from Dr. Warburton (29) , and the −31 luciferase was constructed by the University of Colorado Denver Diabetes and Endocrinology Research Center Molecular Biology Core. PPARγ inhibitor T0070907 (Cayman Chemical) was applied once at 25 μmol/L 24 hours after transfection. Cells were collected, washed with PBS, and resuspended in Luciferase Reporter Lysis Buffer (Promega). After centrifugation, luciferase activity was measured in the supernatant using a Luciferase Assay (Promega) and β-galactosidase activity was measured by absorbance. β-Galactosidase was used for normalization. The data are presented as fold change in relative light units per milliunits of β-galactosidase and represent the average of three independent experiments.
Immunoblot analysis
The following antibodies were used for immunoblotting: Spry4 and Survivin (Santa Cruz Biotech), Wnt7A (R&D Systems), E-cadherin (Cell Signaling), GAPDH, CD82, and β-actin (Abcam). Cell extracts for all immunoblots were prepared in a MAPK lysis buffer. Aliquots of lysates were resolved by 10% SDS-PAGE and transferred to nitrocellulose. The membranes were blocked in TBS with 3% bovine serum albumin and then incubated with primary antibody for 12 to 16 hours at 4°C. Membranes were washed in TBS, incubated with alkaline phosphatasecoupled secondary antibodies for 1 hour at 4°C, and visualized with LumiPhos reagent (Pierce). β-Actin or GAPDH were used as loading controls.
Three-dimensional cell culture, collagen invasion assay, and scratch assay Three-dimensional basement membrane cultures were established as previously described (30) . Briefly, 5,000 cells per well were grown in 2% Matrigel (BD Bioscience) with EGF on a 50% Matrigel base layer. The collagen invasion assay was done as previously described (31) . Briefly, 5,000 cells per well were seeded in 2% Matrigel on a layer of 1:1 collagen (BD Bioscience) to Matrigel mix. Culture growth recorded on day 5. For the scratch assay, cells were grown in complete growth medium until 90% to 100% confluent. A 3-mm space was introduced across the diameter of each plate. At time zero, cells were treated with 1 μg/mL mitomycin to inhibit cell proliferation. Cell migration was recorded at 24 and 48 hours. Images were captured using a ×40 lens on a light microscope and a digital camera.
Matrix metalloproteinase-9 activity assay
The matrix metalloproteinase-9 (MMP-9) Human Biotrak assay (GE Healthcare) was used to measure the levels of active MMP-9 in NSCLC cell lines. Briefly, the assay used 100 μL of cell culture supernatant, a two-site ELISA sandwich format to measure the endogenous levels of active MMP-9 relative to a set of standards. Absorbance was measured at 405 and is presented as fold change in active MMP-9 levels interpolated from the standard curve.
Results

Spry4 expression is lost in NSCLC cell lines
Sixteen NSCLC cell lines were analyzed by QPCR, and decreased Spry4 expression was detected in 21 cell lines relative to the nontransformed human lung epithelial cell line HBEC (the HBEC cell line was cultured in a different media than the NSCLC cell lines; Fig. 1A ). Eleven of 11 dysplastic lung cell cultures analyzed for Spry4 expression also had Wnt7A/Fzd9 signaling increases Spry4 promoter activity through PPARγ in NSCLC PPARγ activation leads to the suppression of growth and the restoration of epithelial differentiation in NSCLC and has been identified as a mediator of Wnt7A/Fzd9 tumor suppression signaling (18, 20) . Previous data indicate that Spry4 expression is increased in response to Wnt7A/Fzd9 pathway activation, indicating that both PPARγ and Spry4 are downstream targets of Wnt7A/Fzd9 (17) . We have previously described H157 and H2122 cell lines as lacking Wnt7a/Fzd9 and Fzd9, respectively, and have generated cell lines with stable Wnt7a and/or Fzd9 expression (17) . We transfected Spry4-luciferase into H157 and H2122 cells with stable Wnt7A and/or Fzd9 expression. In both cell lines, the establishment of the Wnt7A/Fzd9 signaling pathway led to increased Spry4-luciferase activity ( Fig. 2A) . To establish the relationship between PPARγ and Spry4, H157 and H2122 cells were transiently transfected with empty vector, Spry4, or wild-type PPARγ, along with a vector encoding a PPRE luciferase or a Spry4 promoter luciferase. In H157 and H2122 cells, the expression of Spry4 did not lead to increased PPRE luciferase activity (Fig. 2B) . Transfection of PPARγ into H157 and H2122 cells with or without T0070907 (T007), a PPARγ inhibitor, showed increased Spry4 luciferase activity with wild-type PPARγ and decreased activity with T007 treatment (Fig. 2B) . PPARλ did not activate the Spry4 luciferase (data not shown). To further connect PPARγ expression with Spry4 promoter Fig. 2C ). Activity of the Spry4 promoter decreased with sequences smaller than the 1,182 truncation, suggesting that a sequence between 1,182 and 31 bp from the transcription start site in the promoter is needed for the influence of PPARγ on Spry4 promoter activity.
Spry4 reexpression in NSCLC reduces cell growth and colony formation in soft agar and increases expression of tumor suppressors Wnt7A/Fzd9 signaling through PPARγ has been shown to inhibit NSCLC cell growth and reduce colony formation in soft agar (17) . We were interested whether Spry4 contributes to the growth suppression effects of Wnt7A/Fzd9. The role of Spry4 on NSCLC growth was assessed using H157 and H2122 cells stably transfected with Spry4 or an empty vector. Stable expression of Spry4 was confirmed by immunoblot and QPCR (Fig. 3A) . To investigate the influence of Spry4 on transformed cell growth, equal numbers of H157 and H2122 cells with Spry4 reexpression or empty vector control were plated in complete medium, and cell numbers were measured for 6 days. Expression of Spry4 significantly reduced the growth rate of H157 and H2122 cells compared with empty vector control cells (Fig. 3B) . Soft agar assays were used to evaluate the effect of Spry4 expression on colony formation, in which transformed cells are able to grow in an anchorage-independent manner but nontransformed cells are not. After 21 days of observation, stable expression of Spry4 inhibited colony formation compared with empty vector control cells (Fig. 3C) . Apoptotic activity was evaluated in the context of Spry4 expression, and there was no difference in caspase-3 (Fig. 3D ). p53 and its target p21 are well-known members of tumor suppression pathways in the lung (32) . Increased expression of these genes may be related to the inhibition of proliferation observed with Spry4 reexpression. These results show that Spry4 expression reduces cell growth and anchorage-independent growth, two key characteristics of transformed cells.
Spry4 reexpression promotes a mesenchymal to epithelial transition
Because Spry4 expression was increased by PPARγ, we evaluated the effect of Spry4 on the induction of epithelial differentiation. H157 and H2122 cells with stable Spry4 expression were grown in a three-dimensional culture and were observed for 5 days. Cell lines expressing Spry4 exhibited a change in morphologic architecture compared with cell lines expressing the empty vector, demonstrated by the restoration of an organized, spherical structure (Fig. 4A ). E-cadherin is known to regulate the maintenance of an epithelial phenotype (33) . Previous data have shown that E-cadherin is upregulated by Wnt7A/Fzd9 signaling and is involved in the maintenance of an epithelial phenotype (18) . Immuoblot data showed that the expression of Spry4 leads to increased E-cadherin protein expression in H157 and H2122 cell lines compared with empty vector controls (Fig. 4B) . In the context of Spry4 expression, markers of an epithelial state, KRT8 and KRT18, were increased by QPCR, whereas Vimentin, a marker of mesenchymal state, was decreased (Fig. 4C) . These data suggest that Spry4 is involved in promoting the epithelial differentiation stimulated by Wnt7A/Fzd9 signaling.
Spry4 reduces migration and invasion in NSCLC and reduces MMP-9 activity
Spry4 has been observed to inhibit migration in prostate, pancreatic cells, and endothelial cells, but effects of Spry4 on NSCLC migration and invasion have not been investigated (7, 34, 35) . To assess the effects of Spry4 on cell motility, we performed a scratch assay. A 3-mm space was created on confluent plates of H157 and H2122 cells expressing Spry4 or the empty vector. Cells were treated at time zero with 1 μg/mL mitomycin to inhibit proliferation, and the experiment was conducted in triplicate. The cells were photographed at 24 and 48 hours to record the movement of cells into the space created by the lesion. H157 and H2122 cells expressing Spry4 exhibited reduced motility compared with empty vector-transfected cell lines (Fig. 5A) . Invasiveness of cells with stable Spry4 expression was examined using a three-dimensional collagen/Matrigel matrix, as depicted in Fig. 5B . In a chambered glass slide, a layer of 1:1 collagen to Matrigel was applied, followed by a mix of cells, media, and Matrigel (31) . Photographs of cells were taken from above the wells, where cell extensions into the lower collagen layer can be observed. After 5 days of growth, Spry4-expressing cell lines showed reduced invasion into the collagen/Matrigel matrix compared with empty vector-transfected cell lines (Fig. 5B) . The reduction of cell mobility and invasion shown with Spry4 expression suggests that Spry4 may act on downstream targets to inhibit metastasis.
We were also interested in previously unidentified targets of Spry4 that might be related to migration or invasion.
CD82 is a tetraspanin cell surface glycoprotein identified based on its function as a migration suppressor independent of tumor growth and has been identified as a marker of good prognosis in NSCLC (36, 37) . We were interested in a possible role for CD82 in the inhibition of migration and invasion observed with Spry4 reexpression. Spry4 expression resulted in increased CD82 mRNA levels and increased CD82 protein expression by immunoblot (Fig. 5C and  D) . CD82 mRNA expression was decreased by QPCR in 11 NSCLC cell lines compared with nontransformed B2B cell line (data not shown). Nine of those cell lines also had decreased expression of Spry4 compared with B2B, suggesting a correlation between reduced levels of CD82 and Spry4. CD82 has been associated with reduced MMP-9 protein and enzymatic activity in NSCLC (38) . Levels of active MMP-9 were assayed using an ELISA kit and were found to be decreased in Spry4 stably expressing H157 and H2122 cells compared with empty vector controls (Fig. 5E) . Reduced activity of MMP-9 was also observed in the H157 cell line with reexpressed Wnt7A and Fzd9 (data not shown). TIMP1, a negative regulator of MMP-9, was upregulated by QPCR and has been suggested as the link between CD82 and decreased MMP-9 activity ( Fig. 5C; ref. 38 ). These targets of Spry4 may be responsible for the reduction of migration and invasion that was observed with Spry4 reexpression.
Knockdown of Spry4 expression by shRNA leads to reversed expression of epithelial to mesenchymal transition markers and increased cell growth
To assess the effects of loss of Spry4 expression on a nontransformed lung epithelial cell line, B2B cells were stably transfected with shRNA or an shRNA-negative control. Reduction of Spry4 expression was confirmed by immunoblot and QPCR (Fig. 6A and B) . Expression of Spry4 shRNA led to the decreased expression of epithelial markers KRT8 and KRT18, decreased expression of migration suppressor CD82, and decreased expression of growth suppressors p53 and p21 (Fig. 6B) . Increased expression of mesenchymal marker Vimentin was also observed with Spry4 knockdown (Fig. 6B) . In a cell growth assay, loss of Spry4 expression by shRNA led to increased cell growth of B2B cells compared with a negative control (Fig. 6C) . Increased cell growth was observed by an MTS cell proliferation assay when Spry4 expression was knocked down by shRNA in H157 and H2122 cell lines stably expressing Wnt7a/Fzd9 (Fig. 6D) . In the context of Wnt7a/Fzd9 expression in lung epithelial cells, Spry4 expression is important for the inhibition of cell growth. These data suggest that the loss of Spry4 expression in lung epithelial cells could be one step leading to transformation or increased migration and invasion.
Discussion
In this study, we were interested in identifying regulators and targets of Spry4 in NSCLC, about which little was previously known. In a noncanonical Wnt signaling pathway, Wnt7A and Fzd9 have previously been shown to act in a tumor-suppressive manner to reduce cell growth and promote epithelial cell differentiation in NSCLC (17) . Wnt7A/Fzd9 activates PPARγ through an ERK5-dependent pathway and signals to downstream targets such as E-cadherin (18) . Based on our study, Spry4 seems to act as a tumor suppressor in NSCLC. Spry4 promoter activity is increased by PPARγ, a downstream target of Wnt7A/Fzd9 signaling, and affects cell growth, differentiation, motility, and invasion. Figure 7 depicts our proposed signaling model for the Wnt7a and Spry4 pathway. The identification of changes in the expression of genes known to be important in tumor suppression, differentiation, metastasis, and invasion supports the biological effects observed with Spry4 reexpression. Of potential clinical significance is our observation that Spry4 is frequently lost in NSCLC and dysplastic lung epithelial cells.
The regulation of Spry4 expression is still largely undetermined. Tyrosine phosphorylation induced by growth factors has been identified as a positive regulator of Spry, although the phosphorylation is specific to cell type, growth factor, and individual Spry (39) . Spry4 can be induced by FGF, EGF, and platelet-derived growth factor, but unlike Spry1 and Spry2, it does not seem to be phosphorylated in response to growth factor treatment (39, 40) . However, the phosphorylation of mouse Spry4 at Tyr 53 is required for the inhibition of FGF-induced ERK activation (27) . We have shown that the reintroduction of the Wnt7A/Fzd9 signaling pathway in NSCLC cell lines leads to the increased activity of the Spry4 promoter. Loss of Spry4 expression by shRNA in cell lines with stable Wnt7a/Fzd9 expression led to increased cell growth, further strengthening the signaling link between Wnt7A and Spry4. Our data also show that Spry4 is regulated by PPARγ signaling, a novel mode of regulation of Spry4 expression outside of the RTK pathway. We have shown that truncation of the Spry4 promoter leads to reduced activation of Spry4-luc in PPARγ-expressing cell lines; however, no consensus site for PPARγ exists within the promoter region. There is one-half DR1 binding site near −1,600 bp, but its functionality is unknown. Analysis of the Spry4 promoter region has identified many transcription factor binding sites, suggesting complicated regulation of the Spry4 promoter (29) . In our study, the observation of a more gradual decrease in activity, as opposed to a drastic change with a single truncation, suggests that there may be multiple factors working in collaboration to regulate the Spry4 promoter. Further functional analysis is required to determine the regulatory connection between PPARγ and Spry4.
Inhibition of FGF-induced activation of the ERK pathway by Spry4 can occur through binding with Sos1 and is enhanced by heterodimerization with Spry1 (41). In the vascular endothelial growth factor pathway, Spry4 can bind to Raf1 and inhibit Ras-independent inhibition of ERK activation (5) . Spry4 has been shown to interact with testicular protein kinase 1 and lead to the inhibition of integrin-mediated cell spreading (42) . Beyond these examples, the targets of Spry4 are largely unknown. We have shown that Spry4 reexpression leads to increased expression of tumor suppressors p53 and p21. p53 is a well-known negative growth regulator and is frequently lost in NSCLC (43) . p21 negatively regulates cell cycle progression, and loss of p21 results in the failure of cells to undergo cell cycle arrest in response to p53 activation (44) . Upregulation of these tumor suppressors may be related to the observed decrease in cell proliferation and anchorage-independent growth with Spry4 expression.
We observed increased expression of CD82 and TIMP1, and decreased active MMP-9 levels in cells expressing Spry4. We have also observed that active MMP-9 is decreased in H157 cells with stable Wnt7A/Fzd9 expression, although not as significantly. This provides further evidence of a signaling link between Spry4 and Wnt7A. CD82 is ubiquitously expressed in normal tissues and is downregulated in a variety of cancers; in lung cancer, CD82 expression has been associated with good prognosis, and decreased metastasis and invasive potential (36, 37) . In an orthotopic lung tumor model, CD82 dramatically reduced lymph node metastases (45) . CD82 has been shown to upregulate TIMP1 in NSCLC, leading to the suppression of invasion and metastases by inactivating MMP-9 (38). These previous studies support a role for CD82 in the inhibition of invasion and metastasis in our study. Additionally, the CD82 promoter contains a binding motif for p53, which may act synergistically with junB to induce CD82 promoter activity (46) . Increased levels of p53 in our study may be leading to the increased levels of CD82 and, subsequently, decreased migration and invasion.
A mesenchymal to epithelial transition mediated by Wnt7A/Fzd9 may be acting through Spry4 (17) . In normal cells, cadherin-dependent contacts between cells promote proper development and maintenance of normal epithelia (33) . Epithelial tumor cells gradually lose their normal phenotype and acquire more mesenchymal characteristics, with increased motility and invasion (47) . Our findings support a role for Spry4 as a downstream target of Wnt7A/Fzd9 in the mesenchymal to epithelial transition; Spry4 expression induced a more differentiated epithelial phenotype in a three-dimensional culture; induced expression of E-cadherin, KRT8, and KRT18; and suppressed migration and invasion. It is important to note that although Spry4 is a key mediator of the effects of Wnt7A/Fzd9 pathway, the pathway is known to signal to other targets that play a role in its biological effects (48) (49) (50) .
Spry proteins have been found to participate in multiple pathways related to RTK signaling, dependent on cellular context and the specific RTK. Sprys have been shown to antagonize the Ras-ERK MAPK pathway by inhibiting the activation of Ras and Raf1 or to agonize EGF-mediated ERK MAPK signaling through an interaction with c-CBL (3). Spry4, however, does not bind c-CBL and, thus, has not been linked to agonist activity (39) . EGF receptor inhibition by Spry4 was observed in one study using NIH3T3 cells but not in several other studies (6, 26, 27, 41) . In mouse studies, overexpression of Spry4 led to severe pulmonary hypoplasia, and loss of Spry4 led to sustained ERK signaling in response to FGF (26, 51) . The canonical Wnt/β-catenin signaling pathway has been shown to interact with FGF signaling at GSK3β (52) . However, Wnt7A/ Fzd9 signaling does not activate β-catenin signaling, so any interaction with growth factor pathways would occur through an alternate pathway (17, 53) . It may be possible that the Wnt7A/Fzd9 pathway is interacting with growth factor signaling pathways through Spry4 in a manner opposite of the canonical Wnt/β-catenin pathway, leading to tumor suppression instead of promotion. Spry4 could also be activated independent of RTK inhibition depending on the context. Studies are necessary to clarify the range of RTK inhibition by Spry4, the effects of possible dimerization between Sprys on RTK inhibition, and the potential interaction between Wnt and growth factor signaling, all in the context of NSCLC.
Loss of Spry4 expression by shRNA in a nontransformed lung epithelial cell line led to increased cell growth and decreased expression of epithelial markers in our study. These data suggest that Spry4 may influence the transformation of normal lung epithelial cells and may also suppress epithelial to mesenchymal transition in the lung epithelium. Spry4 expression is lost in NSCLC cells and dysplastic lung epithelial cell lines, similar to Wnt7A; however, the timing of loss is unknown (54, 55) . Methylation of Spry4 has been detected in prostate cancer tissue (7) . Wnt5a, another noncanonical, tumor-suppressing Wnt, is methylated in colorectal cancer and leukemia, suggesting the possibility that Wnt7A may also be methylated in NSCLC (56, 57) . Further research needs to be done to establish whether loss of Wnt7A and Spry4 expression are early or late events in lung tumorigenesis and what the mechanism of loss is. We have presented data suggesting that Spry4 is downstream of PPARγ in the Wnt7A/Fzd9 tumor suppression pathway, and that it acts to reduce cell growth, inhibit anchorage-independent growth, suppress migration and invasion, and restore a nontransformed epithelial phenotype. Pharmacologic activation of Spry4 may be a future target for treatment of NSCLC.
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